Second AACR International Meeting: Advances in Malignant Lymphoma: Maximizing the Basic-Translational Interface for Clinical Application
In cooperation with the International Conference on Malignant Lymphoma (ICML)
June 25-28, 2020
Westin Copley Place
Statement Regarding Novel Coronavirus
Last updated April 8, 2020
The AACR continues to closely monitor the evolving developments pertaining to the novel coronavirus (COVID-19). We want to assure colleagues planning to attend any upcoming AACR meetings that safety and security remain our top priorities.
At this time, we are planning to hold the meeting as scheduled. The Second AACR International Meeting on Advances in Malignant Lymphoma: Maximizing the Basic-Translational Interface for Clinical Application, being held in collaboration with the International Conference on Malignant Lymphoma (ICML), will be held from June 25-28, 2020 in Boston, Massachusetts. Therefore, in the event that circumstances do not improve, we are exploring all available options for the meeting, including virtual presentations and postponing the meeting to a later date. We will continue to engage with our stakeholders and monitor new developments in this fluid situation so that we can make the best possible evidence-based decision.
The AACR is tracking all travel restrictions issued by the U.S. Government, as well as information and guidance from the U.S. Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO). We will post further updates here as events warrant. Colleagues who have questions can contact the AACR by email at firstname.lastname@example.org.Statement Regarding Novel Coronavirus: Frequently Asked Questions
Scientific Committee Chair
Ari M. Melnick, Weill Cornell Medical College, New York, New York
Join us for the Second AACR International Meeting: Advances in Malignant Lymphoma: Maximizing the Basic-Translational Interface for Clinical Application, being held in cooperation with the International Conference on Malignant Lymphoma (ICML). This must-attend program will consist of a series of bench-to-bedside debates on critical questions and unmet needs in the lymphoma field, followed by extended, interactive panel discussions. This will provide a dynamic, international forum for discussion and brainstorming among basic scientists, translational researchers, clinical investigators, hematologists, radiotherapists, pediatric oncologists, pathologists, computational and systems biologists, and patient advocates about how recent advances and emerging areas of lymphoma research hold enormous potential for transforming clinical care.
Continuing Medical Education Activity AMA PRA Category 1 CreditsTM available